ArticleBio-protocol2025
Utilizing EdU to Track Leukocyte Recruitment to the Brain.
Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward development of a dynamic supramolecular peptide therapy for acute ischemic stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Detecting the proliferation of cells with copper(I)-catalyzed azide-alkyne cycloaddition (click chemistry) and the thymidine analogue, 5-ethynyl-2'-deoxyuridine (EdU), is a simpler and more versatile method than traditional antibody-based approaches. Instead of the harsh series of steps typically used for 5-bromo-2'-deoxyuridine (BrdU) detection, detecting EdU does not require DNA denaturation and is suitable for use with other applications. This approach was implemented in an animal model of ischemic stroke. The following protocol details how to use EdU to label, track, and visualize leukocyte recruitment for flow cytometry and fluorescence microscopy, including the processes for EdU injection and blood and tissue sample preparation. Considerations for timing, dosing, and cell viability are also outlined to tailor the protocol to experimental needs. This method could be applied to various models that require extended tracking periods, as the signal from EdU can last several cell divisions, depending on cell type and condition. Key features • EdU labeling is simple and compatible with routine laboratory methods. • This method is compatible with genetically encoded fluorophores, such as GFP and tdTomato. • EdU incorporation in circulating leukocytes varies depending on the specific cell subtype. • This technique can be adapted to track leukocyte recruitment, including when cells are recruited from the bloodstream.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.